Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13936400 | 0.85 | NPC1 (0.52) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL23136480 | 0.84 | GPR35 (0.53) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL7537940 | 0.83 | GAA (0.50) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL30758797 | 0.82 | SNCA (0.59) | KMT2ATDP1MEN1CYP2C9CYP2C19 | |
| SCHEMBL4081845 | 0.82 | SNCA (0.59) | KMT2ATDP1MEN1CYP2C9CYP2C19 | |
| SCHEMBL9984654 | 0.82 | MAPT (0.41) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL30955844 | 0.82 | CYP1A2 (0.45) | KMT2ATDP1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL20877511 | 0.82 | CYP1A2 (0.45) | KMT2ATDP1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL30168159 | 0.82 | CYP2C19 (0.62) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL553680 | 0.82 | CYP2C19 (0.62) | LMNAKMT2ATDP1MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3054936-B1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200392077-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-17 | — | — | US | disclosed |
| US-10752581-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190276395-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-09-12 | — | — | US | disclosed |
| US-10266488-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2019-04-23 | — | — | US | disclosed |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-13 | — | — | US | disclosed |
| EP-2844345-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2699569-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145617-A9 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2013177053-A1 | PYRIMIDINO [1, 2 -C] QUINAZOLINONE DERIVATIVES AS TYROSINE KINASES INHIBITORS | ALLERGAN, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130310394-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013165606-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2012145617-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | CBR3, CBR1, CYP1B1 | LMNA 3337/4885KMT2A 3292/4885TDP1 2545/4885 |
| US-10266488-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | ALOX12, ALOX15, ALOX15B | LMNA 1518/4885KMT2A 3941/4885TDP1 4357/4885 |
| US-20200392077-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | ALOX12, ALOX15, ALOX15B | LMNA 1518/4885KMT2A 3941/4885TDP1 4357/4885 |
| US-20190276395-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | ALOX12, ALOX15, ALOX15B | LMNA 1518/4885KMT2A 3941/4885TDP1 4357/4885 |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | LMNA 4054/4885KMT2A 1590/4885TDP1 1037/4885 |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | LMNA 2011/4885KMT2A 1903/4885TDP1 1040/4885 |
| US-10752581-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | ALOX12, ALOX15, ALOX15B | LMNA 1518/4885KMT2A 3941/4885TDP1 4357/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | LMNA 2011/4885KMT2A 1903/4885TDP1 1040/4885 |
| US-20130310394-A1 | KINASE INHIBITORS | CSNK1A1, MAPK1, MAP3K1 | LMNA 3431/4885KMT2A 1812/4885TDP1 1963/4885 |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | RXFP1, RXFP2, RXFP3 | LMNA 2143/4885KMT2A 4449/4885TDP1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.